Biocon sews up chunky patent kitty

IT`S BUSIESS AS USUAL FOR DOMESTIC PHARMACEUTICAL MAJORS

 "In line with this strategy, we are setting up new laboratories to facilitate expansion of our combined research activities. We plan to bring in specialised scientific and regulatory skills and further invest in infrastructure for the biologics pilot plant to produce molecules for Phase I and II clinical trials," she added.

Acknowledging Biocon's contribution for various breakthroughs in medicine, Shrikumar Suryanarayan, president (R&D), was appointed as honorary visiting faculty at the department of molecular medicine, Karolinska Institute, Sweden.

The institute has formally initiated collaboration in research and research education. An MoU was signed between Biocon and Karolinska Institute in this regard.

This partnership will provide valuable access to a world of medical knowledge and scientific training, together with opportunities for exchange of scientists, she further added.